The present invention relates to: TNF-α antagonists containing IGFBP5 protein, variants thereof, or fragments thereof； and the use of the TNF-α antagonists. More specifically, the present invention relates to: a polynucleotide encoding the protein, variants thereof, or fragments thereof； a vector containing the polynucleotide； a transformant containing the vector； and a method for screening a therapeutic agent for TNF-α overexpression-related diseases by checking whether the mutual reaction thereof is facilitated after treating with candidates to the cell expressing the IGFBP5 protein, variants thereof, or fragments thereof, and the TNER1.
